Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 30
1954 266
1955 546
1956 790
1957 596
1958 430
1959 312
1960 258
1961 228
1962 311
1963 540
1964 647
1965 430
1966 467
1967 517
1968 551
1969 552
1970 529
1971 526
1972 518
1973 581
1974 584
1975 545
1976 448
1977 419
1978 409
1979 406
1980 333
1981 385
1982 384
1983 397
1984 377
1985 375
1986 354
1987 296
1988 322
1989 291
1990 261
1991 270
1992 226
1993 233
1994 184
1995 199
1996 170
1997 180
1998 164
1999 159
2000 197
2001 156
2002 147
2003 172
2004 165
2005 168
2006 173
2007 187
2008 160
2009 157
2010 177
2011 172
2012 163
2013 186
2014 159
2015 175
2016 179
2017 177
2018 142
2019 173
2020 197
2021 170
2022 163
2023 151
2024 184
2025 47

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,865 results

Results by year

Filters applied: . Clear all
Page 1
Chlorpromazine-induced lenticular opacity.
Srinivasan K, Gopalakrishna M. Srinivasan K, et al. Indian J Pharmacol. 2020 Jul-Aug;52(4):339-340. doi: 10.4103/ijp.IJP_691_20. Indian J Pharmacol. 2020. PMID: 33078739 Free PMC article. No abstract available.
Chlorpromazine.
ANDERMANN K, LINDSAY JS. ANDERMANN K, et al. Med J Aust. 1955 Jul 16;42(2 3):80-2. Med J Aust. 1955. PMID: 13244000 No abstract available.
Chlorpromazine versus placebo for schizophrenia.
Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Adams CE, et al. Cochrane Database Syst Rev. 2014 Jan 6;2014(1):CD000284. doi: 10.1002/14651858.CD000284.pub3. Cochrane Database Syst Rev. 2014. PMID: 24395698 Free PMC article. Review.
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...AUTHORS' CONCLUSIONS: The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to suppo …
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...AUTHORS' CONCLUS …
Chlorpromazine versus placebo for schizophrenia.
Thornley B, Rathbone J, Adams CE, Awad G. Thornley B, et al. Cochrane Database Syst Rev. 2003;(2):CD000284. doi: 10.1002/14651858.CD000284. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD000284. doi: 10.1002/14651858.CD000284.pub2. PMID: 12804394 Updated. Review.
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...REVIEWER'S CONCLUSIONS: This review will confirm much that clinicians and recipients of care already know, but provides quantification to support clinical i …
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...REVIEWER'S CONCL …
Chlorpromazine versus placebo for schizophrenia.
Thornley B, Adams CE, Awad G. Thornley B, et al. Cochrane Database Syst Rev. 2000;(2):CD000284. doi: 10.1002/14651858.CD000284. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(2):CD000284. doi: 10.1002/14651858.CD000284. PMID: 10796338 Updated. Review.
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for those with schizophrenia. ...Despite the humbling 40% improvement rate in those who were allocated to placebo, chlorpromazine's global position as the 'benchmark' treatment …
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for those with schizophrenia. ...Despite the humbl …
Chlorpromazine retention.
Forrest IS, Forrest FM, Serra MT. Forrest IS, et al. Am J Psychiatry. 1969 Aug;126(2):271-2. doi: 10.1176/ajp.126.2.271. Am J Psychiatry. 1969. PMID: 5804819 No abstract available.
Chlorpromazine-induced SLE.
Weinstein A. Weinstein A. Can Med Assoc J. 1973 Jul 7;109(1):15 passim. Can Med Assoc J. 1973. PMID: 4717085 Free PMC article. No abstract available.
Chlorpromazine versus placebo for schizophrenia.
Adams CE, Awad G, Rathbone J, Thornley B. Adams CE, et al. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD000284. doi: 10.1002/14651858.CD000284.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2014 Jan 06;(1):CD000284. doi: 10.1002/14651858.CD000284.pub3. PMID: 17443500 Updated. Review.
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...AUTHORS' CONCLUSIONS: The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to suppo …
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. ...AUTHORS' CONCLUS …
The introduction of chlorpromazine.
[No authors listed] [No authors listed] Hosp Community Psychiatry. 1976 Jul;27(7):505. Hosp Community Psychiatry. 1976. PMID: 776788 No abstract available.
Chlorpromazine corneal toxicity.
Johnson AW, Buffaloe WJ. Johnson AW, et al. South Med J. 1968 Sep;61(9):993-4. doi: 10.1097/00007611-196809000-00021. South Med J. 1968. PMID: 5676587 No abstract available.
21,865 results
You have reached the last available page of results. Please see the User Guide for more information.